Advertisement

Current Cardiology Reports

, 20:126 | Cite as

The Evolving Cardiovascular Disease Risk Scores for Persons with Diabetes Mellitus

  • Yanglu Zhao
  • Nathan D. Wong
Diabetes and Cardiovascular Disease (ND Wong, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Diabetes and Cardiovascular Disease

Abstract

Purpose of Review

We briefly introduce the concept and use of cardiovascular disease (CVD) risk scores and review the methodology for CVD risk score development and validation in patients with diabetes. We also discuss CVD risk scores for diabetic patients that have been developed in different countries.

Recent Findings

Patients with diabetes have a gradient of CVD risk that needs to be accurately assessed. Numerous CVD risk scores for diabetic patients have been created in various settings. The methods to develop risk scores are highly diverse and each choice has its own pros and cons. A well-constructed risk score for diabetic patients may be advocated by guidelines and adopted by healthcare providers to help determine preventive strategies. New risk factors are being investigated in order to improve the predictive accuracy of current risk scores.

Summary

A suitable CVD risk score for the diabetes population should be accurate, low-cost, and beneficial to outcome. While the performance (accuracy) has all been internally validated, validation on external populations is still needed. Cost-effectiveness and clinical trials demonstrating improvement in outcomes are limited and should be the target of future research.

Keywords

Cardiovascular disease Disease risk score Diabetes 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Zhao has no conflicts to report.

Dr. Wong receives research funding from Amgen, Boehringer-Ingelheim, Amarin, and Pfizer; is a consultant for Astra-Zeneca and Akcea; and is on the speaker’s bureau for Sanofi.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care. 1998;21(7):1138–45.CrossRefGoogle Scholar
  2. 2.
    Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres: the World Health Organisation multinational study of vascular disease in diabetics. Diabetologia. 1985;28:615–40.CrossRefGoogle Scholar
  3. 3.
    Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Shairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–86.CrossRefGoogle Scholar
  4. 4.
    Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.CrossRefGoogle Scholar
  5. 5.
    Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26:142–8.CrossRefGoogle Scholar
  6. 6.
    Howard BV, Best LG, Galloway JM, Howard WJ, Jones K, Lee ET, et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care. 2006;29:391–7.CrossRefGoogle Scholar
  7. 7.
    Zhao Y. Cardiovascular risk assessment and screening in diabetes. Cardiovasc Endocrinol Metab. 2017;6(1):17–22.CrossRefGoogle Scholar
  8. 8.
    Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham study. Am J Cardiol. 1976;38(1):46–51.CrossRefGoogle Scholar
  9. 9.
    D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care the Framingham heart study. Circulation. 2008;117(6):743–53.CrossRefGoogle Scholar
  10. 10.
    Conroy RM, Pyörälä K, Fitzgerald AE, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.CrossRefGoogle Scholar
  11. 11.
    World Health Organization. WHO/ISH cardiovascular risk prediction charts. Prevention of cardiovascular disease: guideline for assessment and management of cardiovascular risk [cited 2018 Aug 12]. Geneva: WHO; 2007.Google Scholar
  12. 12.
    Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297(6):611–9.CrossRefGoogle Scholar
  13. 13.
    Stevens RJ, Kothari V, Adler AI, Stratton IM. United Kingdom prospective diabetes study (UKPDS) group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101(6):671–9.CrossRefGoogle Scholar
  14. 14.
    Poppe KK, Doughty RN, Wells S, Gentles D, Hemingway H, Jackson R, Kerr AJ. Developing and validating a cardiovascular risk score for patients in the community with prior cardiovascular disease. Heart. 2017;103(12):891–892.CrossRefGoogle Scholar
  15. 15.
    Yang X, Li J, Hu D, Chen J, Li Y, Huang J, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese PopulationClinical perspective: the China-PAR project (prediction for ASCVD risk in China). Circulation. 2016;134(19):1430–40.CrossRefGoogle Scholar
  16. 16.
    Jee SH, Jang Y, Oh DJ, Oh BH, Lee SH, Park SW, et al. A coronary heart disease prediction model: the Korean heart study. BMJ Open. 2014;4(5):e005025.CrossRefGoogle Scholar
  17. 17.
    Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935–59.CrossRefGoogle Scholar
  18. 18.
    Stone NJ, Robinson JG, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 part B):2889–934.CrossRefGoogle Scholar
  19. 19.
    Arbogast PG, Ray WA. Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders. Am J Epidemiol. 2011;174(5):613–20.CrossRefGoogle Scholar
  20. 20.
    Kengne AP, Masconi K, Mbanya VN, Lekoubou A, Echouffo-Tcheugui JB, Matsha TE. Risk predictive modelling for diabetes and cardiovascular disease. Crit Rev Clin Lab Sci. 2014;51(1):1–2.CrossRefGoogle Scholar
  21. 21.
    D'Agostino RB Sr, Pencina MJ, Massaro JM, Coady S. Cardiovascular disease risk assessment: insights from Framingham. Glob Heart. 2013;8(1):11–23.CrossRefGoogle Scholar
  22. 22.
    Kengne AP, Patel A, Colagiuri S, et al. The Framingham and UK prospective diabetes study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the action in diabetes and vascular disease: Preterax and Diamicron-MR controlled evaluation (ADVANCE) study. Diabetologia. 2010;53:821–31.CrossRefGoogle Scholar
  23. 23.
    Echouffo-Tcheugui JB, Kengne AP. Comparative performance of diabetes-specific and general population-based cardiovascular risk assessment models in people with diabetes mellitus. Diabetes Metab. 2013;39(5):389–96.CrossRefGoogle Scholar
  24. 24.
    •• Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS. Development and valudation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes Endocrinol. 2017;5:788–98 The RECODe risk scoring system predicts risk for the whole spectrum of diabetes macrovascular and microvascular complications and may better help pick out the high-risk for a specific type of complications among type 2 diabetes patients. CrossRefGoogle Scholar
  25. 25.
    Kengne AP, Patel A, Marre M, Travert F, Lievre M, Zoungas S, et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil. 2011;18(3):393–8.CrossRefGoogle Scholar
  26. 26.
    Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus. Circulation. 2016;133(11):1058–66.CrossRefGoogle Scholar
  27. 27.
    Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjörnsdottir S. Swedish National Diabetes Register. A new model for 5-year risk of cardiovascular disease in type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med. 2011;28(10):1213–20.CrossRefGoogle Scholar
  28. 28.
    Resl M, Clodi M, Vila G, Luger A, Neuhold S, Wurm R, Adlbrecht C, Strunk G, Fritzer-Szekeres M, Prager R, Pacher R. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes. Heart. 2016;102(24):1963–1968.CrossRefGoogle Scholar
  29. 29.
    Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308:788–95.CrossRefGoogle Scholar
  30. 30.
    Yeboah J, Erbel R, Delaney JC, Nance R, Guo M, Bertoni AG, et al. Development of a new diabetes risk prediction tool for incident coronary heart disease events: the multi-ethnic study of atherosclerosis and the Heinz Nixdorf recall study. Atherosclerosis. 2014;236(2):411–7.CrossRefGoogle Scholar
  31. 31.
    Knowles JW, Ashley EA. Cardiovascular disease: the rise of the genetic risk score. PLoS Med. 2018;15(3):e1002546.CrossRefGoogle Scholar
  32. 32.
    Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, et al. Genomic risk prediction of coronary artery disease in nearly 500,000 adults: implications for early screening and primary prevention. BioRxiv. 2018;1:250712.Google Scholar
  33. 33.
    Wilson PW, D’ Agostino RB, Belanger AM, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.CrossRefGoogle Scholar
  34. 34.
    Pepe MS, Kerr KF, Longton G, Wang Z. Testing for improvement in prediction model performance. Stat Med. 2013;32(9):1467–82.CrossRefGoogle Scholar
  35. 35.
    Pepe MS, Fan J, Feng Z, Gerds T, Hilden J. The net reclassification index (NRI): a misleading measure of prediction improvement even with independent test data sets. Stat Biosci. 2015;7(2):282–95.CrossRefGoogle Scholar
  36. 36.
    Van Dieren S, Beulens JW, Kengne AP, Peelen LM, Rutten GE, Woodward M, et al. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart. 2012;98:360–9.CrossRefGoogle Scholar
  37. 37.
    Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom prospective diabetes study: UKPDS 82. Diabetologia. 2013;56(9):1925–33.CrossRefGoogle Scholar
  38. 38.
    Hippisley-Cox J, Coupland C. Development and validation of risk prediction equations to estimate future risk of heart failure in patients with diabetes: a prospective cohort study. BMJ Open. 2015 Sep 1;5(9):e008503.CrossRefGoogle Scholar
  39. 39.
    Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS. Atherosclerosis risk in communities study investigators. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care. 2003;26(10):2777–84.CrossRefGoogle Scholar
  40. 40.
    Lagani V, Chiarugi F, Thomson S, Fursse J, Lakasing E, Jones RW, et al. Development and validation of risk assessment models for diabetes-related complications based on the DCCT/EDIC data. J Diabetes Complicat. 2015;29(4):479–87.CrossRefGoogle Scholar
  41. 41.
    Goliasch G, Silbernagel G, Kleber ME, Grammer TB, Pilz S, Tomaschitz A, et al. Refining long-term prediction of cardiovascular risk in diabetes–the VILDIA score. Sci Rep. 2017;7(1):4700.CrossRefGoogle Scholar
  42. 42.
    Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the steno type 1 risk engine. Circulation. 2016;133(11):1058–66.CrossRefGoogle Scholar
  43. 43.
    • Wan EYF, Fong DYT, Fung CSC, Yu EYT, Chin WY, Chan AKC, et al. Development of a cardiovascular diseases risk prediction model and tools for Chinese patients with type 2 diabetes mellitus: A population-based retrospective cohort study. Diabetes Obes Metab. 2018;(2):309–318.  https://doi.org/10.1111/dom.13066. This CVD risk score for Chinese diabetic population is the latest DM-specific risk score with the most contemporary cohort.CrossRefGoogle Scholar
  44. 44.
    Woodward M, Hirakawa Y, Kengne AP, Matthews DR, Zoungas S, Patel A, et al. Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score. Diabetes Obes Metab. 2016;18(3):289–94.CrossRefGoogle Scholar
  45. 45.
    Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK prospective diabetes study risk engine. Stroke. 2002;33(7):1776–81.CrossRefGoogle Scholar
  46. 46.
    Lundqvist A, Carlsson KS, Johansen P, Andersson E, Willis M. Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations. PLoS One. 2014;9(10):e110235.CrossRefGoogle Scholar
  47. 47.
    Parrinello CM, Matsushita K, Woodward M, Wagenknecht LE, Coresh J, Selvin E. Risk prediction of major complications in individuals with diabetes: the a therosclerosis R isk in C ommunities S tudy. Diabetes Obes Metab. 2016;18(9):899–906.CrossRefGoogle Scholar
  48. 48.
    Basu S, Sussman JB, Berkowitz SA, Hayward RA, Bertoni AG, Correa A, Mwasongwe S, Yudkin JS. Validation of risk equations for complications of type 2 diabetes (RECODe) using individual participant data from diverse longitudinal cohorts in the US. Diabetes care. 2017:dc172002.Google Scholar
  49. 49.
    Zethelius B, Eliasson B, Eeg-Olofsson K, Svensson AM, Gudbjörnsdottir S, Cederholm J. A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract. 2011;93(2):276–84.  https://doi.org/10.1016/j.diabres.2011.05.037.CrossRefGoogle Scholar
  50. 50.
    Read SH, van Diepen M, Colhoun HM, Halbesma N, Lindsay RS, McKnight JA, McAllister DA, Pearson ER, Petrie JR, Philip S, Sattar N. Performance of cardiovascular disease risk scores in people diagnosed with type 2 diabetes: external validation using data from the national Scottish diabetes register. Diabetes care. 2018:dc180578.Google Scholar
  51. 51.
    Jardine MJ, Hata J, Woodward M, Perkovic V, Ninomiya T, Arima H, et al. Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis. 2012;60(5):770–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of EpidemiologyUniversity of California Los Angeles Fielding School of Public HealthLos AngelesUSA
  2. 2.Heart Disease Prevention ProgramUniversity of California, IrvineIrvineUSA

Personalised recommendations